ReviewCurrent pharmaceutical design2012
P53 mdm2 inhibitors.
Review in Current pharmaceutical design, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 40 citations in OpenAlex.
- Participation of MDM2 in Pro-Apoptotic and Androgen Receptor- Degrading Potency of Selected Steroid and Terpenoid Derivatives.Current medicinal chemistry · 2026Review
- Multi-Step Synthesis of Chimeric Nutlin-DCA Compounds Targeting Dual Pathways for Treatment of Cancer.Molecules (Basel, Switzerland) · 2025Article
- Dual treatment with Val-083 and AZD1775 shows potent anti-tumor activity in diffuse midline glioma models.NPJ precision oncology · 2025Article
- Dysregulated Signalling Pathways Driving Anticancer Drug Resistance.International journal of molecular sciences · 2023Review
- Mutational Damages in Malignant Lung Tumors.Asian Pacific journal of cancer prevention : APJCP · 2023Article
- Functional roles of E3 ubiquitin ligases in prostate cancer.Journal of molecular medicine (Berlin, Germany) · 2022Review
- The Role of p53 Expression in Patients with RAS/BRAF Wild-Type Metastatic Colorectal Cancer Receiving Irinotecan and Cetuximab as Later Line Treatment.Targeted oncology · 2021Article
- Therapeutic opportunities in cancer therapy: targeting the p53-MDM2/MDMX interactions.American journal of cancer research · 2021Review
- Autophagy promotes mammalian survival by suppressing oxidative stress and p53.Genes & development · 2020Article
- Recent Small-Molecule Inhibitors of the p53-MDM2 Protein-Protein Interaction.Molecules (Basel, Switzerland) · 2020Review
- Anticancer Effects of Constituents of Herbs Targeting Osteosarcoma.Chinese journal of integrative medicine · 2019Review
- The MALDI-TOF E2/E3 Ligase Assay as Universal Tool for Drug Discovery in the Ubiquitin Pathway.Cell chemical biology · 2018Article
- Oridonin Targets Multiple Drug-Resistant Tumor Cells as Determined byFrontiers in pharmacology · 2018Article
- Development of a novel immunoassay to detect interactions with the transactivation domain of p53: application to screening of new drugs.Scientific reports · 2017Article
- The role of p53 in cancer drug resistance and targeted chemotherapy.Oncotarget · 2017Review
- Chemical Variations on the p53 Reactivation Theme.Pharmaceuticals (Basel, Switzerland) · 2016Review
- Energetic Landscape of MDM2-p53 Interactions by Computational Mutagenesis of the MDM2-p53 Interaction.PloS one · 2016Article
- In vitro cytotoxicity and in vivo efficacy, pharmacokinetics, and metabolism of pyrazole-based small molecule inhibitors of Mdm2/4-p53 interaction.Cancer chemotherapy and pharmacology · 2015Article
- Article
- Targeting ubiquitination for cancer therapies.Future medicinal chemistry · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The protein-protein interaction (PPI) between p53 and its negative regulator MDM2 comprises one of the most important and intensely studied PPI's involved in preventing the initiation of cancer. The interaction between p53 and MDM2 is conformation-based and is tightly regulated on multiple levels. Due to the Angstrom level structural insight there is a reasonable understanding of the structural requirements needed for a molecule to bind to MDM2 and successfully inhibit the p53/MDM2 interaction. The current review summarizes the binding characteristics of the different disclosed small molecules for inhibition of MDM2 with a co-crystal structure. Synthetic access to these compounds as well as their derivatives are described in detail.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.